Peter Kim disclosed this on MRK’s Dec 9 R&D webcast. It looks like DVAX sat on the bad news for Heplisav until it could report the good news re the GSK deal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”